Patient characteristics for the ESPOIR Trial and the ESPOIR Registry cohort, and the respective matched CH and BJV cohorts
| . | The ESPOIR Trial cohort and matched pairs . | The ESPOIR Registry cohort and matched pairs . | ||||
|---|---|---|---|---|---|---|
| . | DPH . | CH . | BJV . | DPH . | CH . | BJV . |
| Implantation period | 2014–2016 | 1988–2015 | 2000–2016 | 2005–2018 | 1985–2014 | 1999–2012 |
| Diagnoses (%) | ||||||
| TOF | 44 | 35 | 54 | 48 | 49 | 68 |
| Ross | 21 | 41 | 10 | 11 | 21 | 7 |
| PI/PS | 14 | 6 | 10 | 17 | 5 | 5 |
| PA | 10 | 9 | 11 | 13 | 8 | 6 |
| DORV | 5 | 1 | 7 | 4 | 8 | 6 |
| TAC | 4 | 4 | 6 | 4 | 4 | 4 |
| TGA | 1 | 3 | 2 | 3 | 4 | 2 |
| Other | 1 | 1 | 0 | 0 | 1 | 2 |
| Total (n) | 121 | 121 | 121 | 114 | 114 | 114 |
| Age at implantation (years), mean (SD) | 21.4 (14.4) | 21.2 (14.6) | 17.6 (11.6) | 16.6 (10.4) | 16.5 (10.6) | 15.6 (9.2) |
| Follow-up (years), mean (SD) | 2.2 (0.6) | 5.2 (4.4) | 4.1 (3.7) | 6.0 (3.5) | 5.1 (5.1) | 4.4 (3.3) |
| Total follow-up (years) | 93 | 781 | 715 | 578 | 862 | 738 |
| Sex (male), n (%) | 61 (50) | 71 (59) | 66 (55) | 75 (66%) | 72 (63) | 54 (47) |
| Number of previous operations | ||||||
| 0 | 11 | 28 | 8 | 17 | 21 | 11 |
| 1 | 62 | 51 | 75 | 60 | 53 | 65 |
| 2 | 32 | 29 | 24 | 24 | 33 | 27 |
| >2 | 16 | 13 | 14 | 13 | 7 | 11 |
| Conduit diameter (mm), mean (SD) | 24.4 (2.8) | 24.2 (2.8) | 20.6 (2.3) | 24.1 (4.2) | 23.5 (3.6) | 20.1 (2.9) |
| 12–19 | 6 | 6 | 25 | 15 | 13 | 30 |
| 20–23 | 37 | 47 | 96 | 34 | 37 | 82 |
| 24–29 | 78 | 68 | 0 | 65 | 64 | 2 |
| . | The ESPOIR Trial cohort and matched pairs . | The ESPOIR Registry cohort and matched pairs . | ||||
|---|---|---|---|---|---|---|
| . | DPH . | CH . | BJV . | DPH . | CH . | BJV . |
| Implantation period | 2014–2016 | 1988–2015 | 2000–2016 | 2005–2018 | 1985–2014 | 1999–2012 |
| Diagnoses (%) | ||||||
| TOF | 44 | 35 | 54 | 48 | 49 | 68 |
| Ross | 21 | 41 | 10 | 11 | 21 | 7 |
| PI/PS | 14 | 6 | 10 | 17 | 5 | 5 |
| PA | 10 | 9 | 11 | 13 | 8 | 6 |
| DORV | 5 | 1 | 7 | 4 | 8 | 6 |
| TAC | 4 | 4 | 6 | 4 | 4 | 4 |
| TGA | 1 | 3 | 2 | 3 | 4 | 2 |
| Other | 1 | 1 | 0 | 0 | 1 | 2 |
| Total (n) | 121 | 121 | 121 | 114 | 114 | 114 |
| Age at implantation (years), mean (SD) | 21.4 (14.4) | 21.2 (14.6) | 17.6 (11.6) | 16.6 (10.4) | 16.5 (10.6) | 15.6 (9.2) |
| Follow-up (years), mean (SD) | 2.2 (0.6) | 5.2 (4.4) | 4.1 (3.7) | 6.0 (3.5) | 5.1 (5.1) | 4.4 (3.3) |
| Total follow-up (years) | 93 | 781 | 715 | 578 | 862 | 738 |
| Sex (male), n (%) | 61 (50) | 71 (59) | 66 (55) | 75 (66%) | 72 (63) | 54 (47) |
| Number of previous operations | ||||||
| 0 | 11 | 28 | 8 | 17 | 21 | 11 |
| 1 | 62 | 51 | 75 | 60 | 53 | 65 |
| 2 | 32 | 29 | 24 | 24 | 33 | 27 |
| >2 | 16 | 13 | 14 | 13 | 7 | 11 |
| Conduit diameter (mm), mean (SD) | 24.4 (2.8) | 24.2 (2.8) | 20.6 (2.3) | 24.1 (4.2) | 23.5 (3.6) | 20.1 (2.9) |
| 12–19 | 6 | 6 | 25 | 15 | 13 | 30 |
| 20–23 | 37 | 47 | 96 | 34 | 37 | 82 |
| 24–29 | 78 | 68 | 0 | 65 | 64 | 2 |
BJV: bovine jugular vein; CH: cryopreserved homograft; DPH: decellularized pulmonary homografts; SD: standard deviation.
Patient characteristics for the ESPOIR Trial and the ESPOIR Registry cohort, and the respective matched CH and BJV cohorts
| . | The ESPOIR Trial cohort and matched pairs . | The ESPOIR Registry cohort and matched pairs . | ||||
|---|---|---|---|---|---|---|
| . | DPH . | CH . | BJV . | DPH . | CH . | BJV . |
| Implantation period | 2014–2016 | 1988–2015 | 2000–2016 | 2005–2018 | 1985–2014 | 1999–2012 |
| Diagnoses (%) | ||||||
| TOF | 44 | 35 | 54 | 48 | 49 | 68 |
| Ross | 21 | 41 | 10 | 11 | 21 | 7 |
| PI/PS | 14 | 6 | 10 | 17 | 5 | 5 |
| PA | 10 | 9 | 11 | 13 | 8 | 6 |
| DORV | 5 | 1 | 7 | 4 | 8 | 6 |
| TAC | 4 | 4 | 6 | 4 | 4 | 4 |
| TGA | 1 | 3 | 2 | 3 | 4 | 2 |
| Other | 1 | 1 | 0 | 0 | 1 | 2 |
| Total (n) | 121 | 121 | 121 | 114 | 114 | 114 |
| Age at implantation (years), mean (SD) | 21.4 (14.4) | 21.2 (14.6) | 17.6 (11.6) | 16.6 (10.4) | 16.5 (10.6) | 15.6 (9.2) |
| Follow-up (years), mean (SD) | 2.2 (0.6) | 5.2 (4.4) | 4.1 (3.7) | 6.0 (3.5) | 5.1 (5.1) | 4.4 (3.3) |
| Total follow-up (years) | 93 | 781 | 715 | 578 | 862 | 738 |
| Sex (male), n (%) | 61 (50) | 71 (59) | 66 (55) | 75 (66%) | 72 (63) | 54 (47) |
| Number of previous operations | ||||||
| 0 | 11 | 28 | 8 | 17 | 21 | 11 |
| 1 | 62 | 51 | 75 | 60 | 53 | 65 |
| 2 | 32 | 29 | 24 | 24 | 33 | 27 |
| >2 | 16 | 13 | 14 | 13 | 7 | 11 |
| Conduit diameter (mm), mean (SD) | 24.4 (2.8) | 24.2 (2.8) | 20.6 (2.3) | 24.1 (4.2) | 23.5 (3.6) | 20.1 (2.9) |
| 12–19 | 6 | 6 | 25 | 15 | 13 | 30 |
| 20–23 | 37 | 47 | 96 | 34 | 37 | 82 |
| 24–29 | 78 | 68 | 0 | 65 | 64 | 2 |
| . | The ESPOIR Trial cohort and matched pairs . | The ESPOIR Registry cohort and matched pairs . | ||||
|---|---|---|---|---|---|---|
| . | DPH . | CH . | BJV . | DPH . | CH . | BJV . |
| Implantation period | 2014–2016 | 1988–2015 | 2000–2016 | 2005–2018 | 1985–2014 | 1999–2012 |
| Diagnoses (%) | ||||||
| TOF | 44 | 35 | 54 | 48 | 49 | 68 |
| Ross | 21 | 41 | 10 | 11 | 21 | 7 |
| PI/PS | 14 | 6 | 10 | 17 | 5 | 5 |
| PA | 10 | 9 | 11 | 13 | 8 | 6 |
| DORV | 5 | 1 | 7 | 4 | 8 | 6 |
| TAC | 4 | 4 | 6 | 4 | 4 | 4 |
| TGA | 1 | 3 | 2 | 3 | 4 | 2 |
| Other | 1 | 1 | 0 | 0 | 1 | 2 |
| Total (n) | 121 | 121 | 121 | 114 | 114 | 114 |
| Age at implantation (years), mean (SD) | 21.4 (14.4) | 21.2 (14.6) | 17.6 (11.6) | 16.6 (10.4) | 16.5 (10.6) | 15.6 (9.2) |
| Follow-up (years), mean (SD) | 2.2 (0.6) | 5.2 (4.4) | 4.1 (3.7) | 6.0 (3.5) | 5.1 (5.1) | 4.4 (3.3) |
| Total follow-up (years) | 93 | 781 | 715 | 578 | 862 | 738 |
| Sex (male), n (%) | 61 (50) | 71 (59) | 66 (55) | 75 (66%) | 72 (63) | 54 (47) |
| Number of previous operations | ||||||
| 0 | 11 | 28 | 8 | 17 | 21 | 11 |
| 1 | 62 | 51 | 75 | 60 | 53 | 65 |
| 2 | 32 | 29 | 24 | 24 | 33 | 27 |
| >2 | 16 | 13 | 14 | 13 | 7 | 11 |
| Conduit diameter (mm), mean (SD) | 24.4 (2.8) | 24.2 (2.8) | 20.6 (2.3) | 24.1 (4.2) | 23.5 (3.6) | 20.1 (2.9) |
| 12–19 | 6 | 6 | 25 | 15 | 13 | 30 |
| 20–23 | 37 | 47 | 96 | 34 | 37 | 82 |
| 24–29 | 78 | 68 | 0 | 65 | 64 | 2 |
BJV: bovine jugular vein; CH: cryopreserved homograft; DPH: decellularized pulmonary homografts; SD: standard deviation.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
